Evidence map›Paper›PMID 35847513›Full record

ArticleActa pharmaceutica Sinica. B2022

Discovery of

Sameera Senaweera, Tiffany C Edwards, Jayakanth Kankanala, Yan Wang, Rajkumar Lalji Sahani, Jiashu Xie, Robert J Geraghty, Zhengqiang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sameera SenaweeraCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Tiffany C EdwardsCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Jayakanth KankanalaCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Yan WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Rajkumar Lalji SahaniCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Jiashu XieCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Robert J GeraghtyCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Zhengqiang WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.

Funding

Discovery and development of novel anti-HCMV agents targeting the UL89 terminase proteinR01AI136982 · NIAID · UNIVERSITY OF MINNESOTA · PI GERAGHTY, ROBERT JAMES, WANG, ZHENGQIANG · 2019 to 2023
$3.3M
NIAID NIH HHS R01 AI136982
6 · The paper itself

Abstract

Current drugs for treating human cytomegalovirus (HCMV) infections are limited by resistance and treatment-associated toxicities. In developing mechanistically novel HCMV antivirals, we discovered an

Indexed as

Human cytomegalovirusMechanism of actionN-Benzyl hydroxypyridone carboxamidesStructure–activity relationship

Identifiers

PMID35847513
PMCPMC9279720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.